Blaze Bioscience Inc. Announces Initiation Of First-In-Human Phase 1 Clinical Study Of BLZ-100

Published: Dec 19, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE & MELBOURNE, Australia--(BUSINESS WIRE)--Blaze Bioscience, Inc. and its subsidiary, Blaze Bioscience Australia Pty Ltd, today announced the initiation of the first Phase 1 clinical study of the first Tumor Paint product candidate, BLZ-100. The study, titled “A Phase I Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Skin Cancer,” will enroll up to 30 patients with basal cell carcinoma, squamous cell carcinoma, or amelanotic melanoma. The primary objective is to evaluate the safety and tolerability of BLZ-100 after a single intravenous injection of BLZ-100 administered prior to surgery. The study will also examine the pharmacokinetics of BLZ-100 and the fluorescent signal from skin tumors.

Help employers find you! Check out all the jobs and post your resume.

Back to news